PT  - JOURNAL ARTICLE
AU  - Catherine Le Moine
AU  - Per Svenningsson
AU  - Bertil B. Fredholm
AU  - Bertrand Bloch
TI  - Dopamine–Adenosine Interactions in the Striatum and the Globus Pallidus: Inhibition of Striatopallidal Neurons through Either D<sub>2</sub>  or A<sub>2A</sub> Receptors Enhances D<sub>1</sub>Receptor-Mediated Effects  on <em>c-fos</em> Expression
AID  - 10.1523/JNEUROSCI.17-20-08038.1997
DP  - 1997 Oct 15
TA  - The Journal of Neuroscience
PG  - 8038--8048
VI  - 17
IP  - 20
4099  - http://www.jneurosci.org/content/17/20/8038.short
4100  - http://www.jneurosci.org/content/17/20/8038.full
SO  - J. Neurosci.1997 Oct 15; 17
AB  - D1 receptors located on striatonigral neurons and D2 receptors located, together with A2Areceptors, on striatopallidal neurons are known to interact functionally. Using in situ hybridization, we examined the effects of D1 and D2 agonists and of an A2A antagonist on c-fos mRNA in identified striatal neurons and in globus pallidus. The full D1agonist, SKF 82958 (1 mg/kg), induced a homogenous increase ofc-fos mRNA in the striatum. This increase occurred to a similar extent in D1 and D2 receptor-containing striatal neurons. Conversely, the D2 agonist, quinelorane (2 mg/kg), decreased c-fos mRNA in these populations but increased it in globus pallidus. The adenosine A2A receptor antagonist, SCH 58261 (5 mg/kg), also decreased c-fosmRNA in D2 receptor-containing neurons in striatum but did not affect pallidal c-fos mRNA. Concomitant administration of either D1 plus D2 agonists or D1 agonist plus A2A antagonist caused a potentiation of c-fos mRNA in striatal neurons expressing the D1 receptor and in globus pallidus. However, only the combination of D1 and D2 agonists modified the c-fos mRNA expression to a “patchy” distribution. Our data show that (1) c-fos expression can be activated through D1 and inhibitedthrough A2A or D2 receptors in both striatal output pathways in normal rats, and (2) D2 receptor stimulation as well as A2A receptor blockade can interact with D1 receptor activation to potentiatec-fos expression in the striatum and the globus pallidus. The data also suggest that the topological alteration ofc-fos expression after coadministration of D1 and D2 agonists involves D2receptors located on interneurons or presynaptically on dopaminergic nerve terminals.